Pharmacokinetics and Biodistribution of 89Zr-Miltuximab and Its Antibody Fragments as Glypican‑1 Targeting Immuno-PET Agents in Glioblastoma

• Published in: Molecular pharmaceutics Vol. 20; no. 3; pp. 1549 - 1563
• Main Authors: Ghosh, Saikat, Fletcher, Nicholas L., Huda, Pie, Houston, Zachary H., Howard, Christopher B., Lund, Maria E., Lu, Yanling, Campbell, Douglas H., Walsh, Bradley J., Thurecht, Kristofer J.
• Format: Journal Article
• Language: English
• Published: American Chemical Society 06.03.2023
• Subjects: pharmacokinetics; antibody fragments; biodistribution; glioblastoma; glypican-1; PET

Glioblastoma (GBM) is the most aggressive form of primary brain cancer, accounting for about 85% of all primary central nervous system (CNS) tumors. With standard treatment strategies like surgery, radiation, and chemotherapy, the median survival time of patients with GBM is only 12–15 months from d...